Antares Pharma Incorporated saw dramatic falls in its stock price after hitting a roadblock in clinical trials of its prescription testosterone product. A patient developed an allergic reaction to the drug during the trial, causing the U.S. Food and Drug Administration (FDA) to request additional safety information. A Reuters’ article discusses the setback for the testosterone therapy manufacturer.
Concerns over the safety of prescription testosterone products have ...
continue reading...